Sodium Valproate and Surgical Mesh Implants: Compensation
The question
To ask the Secretary of State for Health and Social Care, with reference to the Patient Safety Commissioner's report entitled The Hughes Report: Options for redress for those harmed by valproate and pelvic mesh, published on 7 February 2024, what assessment his Department has made of the impact of sodium valproate on families affected by fetal valproate syndrome in Northern Ireland; and what steps his Department is taking to ensure a UK-wide redress scheme for those affected by that syndrome.
Answered by Andrew Gwynne
The impact of sodium valproate on families affected by fetal valproate syndrome in Northern Ireland is a transferred matter and is the responsibility of the Northern Ireland Executive, therefore an assessment has not been made by the Department of Health and Social Care.
The Government is carefully considering the valuable work done by the Patient Safety Commissioner and the resulting Hughes Report, which set out options for redress for those harmed by valproate and pelvic mesh. We will be providing an update to the Patient Safety Commissioner’s report at the earliest opportunity. Although the Hughes Report and its recommendations only cover patients harmed in England, the Government recognises that any response will likely have implications for the whole of the United Kingdom, and is engaging with the devolved administrations on the Hughes Report.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →